US stock · Healthcare sector · Medical Devices
Company Logo

Boston Scientific Corporation

BSXNYSE

41.20

USD
+1.06
(+2.64%)
After Hours Market
75.74P/E
20Forward P/E
2.92P/E to S&P500
58.898BMarket CAP
- -Div Yield
Upcoming Earnings
25 Jul-29 Jul
Shares Short
5/13/22
15M
Short % of Float
1.05%
Short % of Shares Outs.
1.05%
% Held by Insiders
0.24%
% Held by Institutions
92.95%
Beta
0.81
PEG Ratio
2.22
52w. high/low
47.50/37.96
Avg. Daily Volume
8.71M
Return %
Stock
S&P 500
1 year
(4.45)
(5.39)
3 years
5.19
40.55
5 years
46.71
64.79
Scale: |
High
Low
18.69
11.27
14.22
5.41
11.77
6.08
9.79
5.04
7.96
5.01
6.41
4.79
12.48
5.76
14.08
11.10
19.06
13.14
24.79
15.67
29.93
21.66
39.44
24.84
46.62
32.73
46.13
24.10
46.29
34.58
47.50
37.99
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
6.14
5.62
5.37
5.43
5.14
5.05
5.15
5.33
5.57
5.57
6.18
6.60
7.11
7.71
7.00
8.39
8.54
Earnings per share
(2.81)
(0.33)
(1.36)
(0.68)
(0.70)
0.29
(2.89)
(0.09)
(0.09)
(0.18)
0.26
0.08
1.21
3.38
(0.06)
0.73
0.53
FCF per share
1.18
0.38
0.57
0.31
0.03
0.47
0.74
0.62
0.76
0.26
0.44
0.81
(0.00)
0.99
0.80
0.93
0.92
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.02
0.04
0.04
CAPEX per share
0.27
0.24
0.24
0.24
0.18
0.20
0.16
0.18
0.20
0.18
0.28
0.23
0.23
0.33
0.27
0.39
0.39
Book Value per sh.
12.02
10.15
8.79
8.16
7.44
7.52
4.88
4.88
4.88
4.71
4.96
5.12
6.32
9.97
10.82
11.73
11.36
Comm.Shares outs.
1,273
1,487
1,499
1,508
1,518
1,509
1,407
1,341
1,324
1,341
1,358
1,370
1,381
1,392
1,417
1,417
1,425
Avg. annual P/E ratio
(6.8)
(44.5)
(8.5)
(13.5)
(9.6)
22.8
(2.0)
(106.1)
(142.8)
(95.8)
82.9
346.9
26.5
11.9
(642.7)
56.3
75.7
P/E to S&P500
(0.4)
(2.6)
(0.4)
(0.2)
(0.5)
1.4
(0.1)
(6.2)
(7.9)
(4.8)
3.7
14.7
1.1
0.5
(17.0)
1.9
2.9
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.1%
0.1%
0.1%
Revenue (m)
7,821
8,357
8,050
8,188
7,806
7,622
7,249
7,143
7,380
7,477
8,386
9,048
9,823
10,735
9,913
11,888
12,162
Operating margin
(37.7)%
(0.2)%
(18.7)%
(10.9)%
(8.4)%
11.9%
(53.4)%
1.7%
(4.1)%
(4.4)%
5.3%
14.2%
15.3%
14.1%
(0.8)%
10.1%
10.8%
Depreciation (m)
781
939
864
834
816
717
683
689
725
769
815
844
894
1,011
1,123
1,093
1,023
Net profit (m)
(3,577)
(495)
(2,036)
(1,025)
(1,065)
441
(4,068)
(121)
(119)
(239)
347
104
1,671
4,700
(82)
1,041
810
Income tax rate
(1.2)%
13.0%
(0.2)%
21.6%
(0.2)%
31.3%
0.9%
45.7%
76.6%
63.2%
(96.0)%
88.7%
(17.5)%
(584.1)%
(2.5)%
3.3%
9.8%
Net profit margin
(45.7)%
(5.9)%
(25.3)%
(12.5)%
(13.6)%
5.8%
(56.1)%
(1.7)%
(1.6)%
(3.2)%
4.1%
1.1%
17.0%
43.8%
(0.8)%
8.8%
6.8%
Working capital (m)
2,271
2,671
2,219
1,039
1,006
1,298
1,250
1,187
760
1,041
(348)
(1,832)
(1,257)
(167)
3,013
2,043
2,043
Long-term debt (m)
8,895
7,933
6,743
5,915
4,934
4,257
4,252
4,237
3,859
5,674
5,420
3,776
4,771
8,579
9,118
9,190
9,190
Equity (m)
15,298
15,097
13,174
12,301
11,296
11,353
6,870
6,539
6,457
6,320
6,733
7,011
8,725
13,877
15,327
16,623
16,623
ROIC
(12.6)%
(1.8)%
(6.6)%
(3.2)%
(3.4)%
3.3%
(24.8)%
0.4%
(0.5)%
(0.9)%
5.5%
1.0%
12.4%
30.9%
1.1%
4.9%
4.7%
Return on capital
(11.4)%
(1.8)%
(5.8)%
(3.6)%
(3.0)%
4.3%
(22.4)%
0.6%
(1.7)%
(2.0)%
2.3%
6.1%
7.9%
3.8%
0.9%
4.4%
4.5%
Return on equity
(23.4)%
(3.3)%
(15.5)%
(8.3)%
(9.4)%
3.9%
(59.2)%
(1.9)%
(1.8)%
(3.8)%
5.2%
1.5%
19.2%
33.9%
(0.5)%
6.3%
4.9%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
134.1%
94.7%
94.7%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
66.9%
- -
- -
- -
- -
(18.6)%
(7.7)%
1,683.3%
(8.9)%
- -
4.2%
4.2%
Capital Structure
23 Feb · 2022 | Q4
All numbers in millions
Total liabilities
$ 15,607
Total assets
$ 32,229
Long-term debt
$ 9,190
Cash and equiv.
$ 1,925
Goodwill
$ 11,988
Retained earnings
$ (1,392)
Common stock
1,428
Enterprise Value
$ 66,163
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
217
1,734
1,925
Receivables
1,933
1,531
1,778
Inventory
1,579
1,351
1,610
Other
970
3,595
2,712
Current assets
4,699
6,694
6,317
Acc. Payable
542
513
794
Debt due
1,416
13
261
Other
2,908
3,155
3,219
Current liabilities
4,866
3,681
4,274
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
19.92%
7.53%
5.93%
Cash flow
16.25%
(5,779.66)%
(2,558.61)%
Earnings
(1,369.51)%
54.19%
(10.70)%
Dividends
96.43%
- -
- -
Book value
8.46%
25.60%
11.65%
Insider Trading
Type
Shares
Date
Carruthers Wendy
Sale
7,500
05/16/22
Dockendorff Charles J
Award
4,877
05/05/22
Connors Nelda J
Award
4,877
05/05/22
Fujimori Yoshiaki
Award
4,877
05/05/22
James Donna
Award
4,877
05/05/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
2,543
2,003
2,659
2,709
9,914
2021
2,752
3,077
2,932
3,127
11,888
2022
3,026
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.01
(0.10)
(0.11)
0.15
(0.06)
2021
0.24
0.13
0.30
0.07
0.73
2022
0.08
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
0.01
0.01
2021
0.01
0.01
0.01
0.01
0.04
Company Description
Sector:
Healthcare
Industry:
Medical Devices
CEO:
Mr. Michael Mahoney
Full-time employees:
41,000
City:
Marlborough
Address:
300 BOSTON SCIENTIFIC WAY
IPO:
May 19, 1992
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.